Article in Nanoscale, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Alexandra Brito3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal. rpires@i3bs.uminho.pt pashkuleva@i3bs.uminho.pt and ICVS/3Bs - PT Government Associate Laboratory, Braga/Guimarães, Portugal and Department of Radiology, Memorial Sloan Kettering Cancer Center, USA and Advanced Science Research Center (ASRC) at the Graduate Center, City University of New York (CUNY), 85 St Nicholas Terrace, New York, New York 10031, USA.ORCID http://orcid.org/0000-0002-5027-4080
Rui L Reis3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal. rpires@i3bs.uminho.pt pashkuleva@i3bs.uminho.pt and ICVS/3Bs - PT Government Associate Laboratory, Braga/Guimarães, Portugal.ORCID http://orcid.org/0000-0002-4295-6129
Rein V UlijnAdvanced Science Research Center (ASRC) at the Graduate Center, City University of New York (CUNY), 85 St Nicholas Terrace, New York, New York 10031, USA and Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York 10065, USA and PhD programs in Biochemistry and Chemistry, The Graduate Center of the City University of New York, New York 10016, USA.ORCID http://orcid.org/0000-0002-7138-1213
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, USA and Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA and Department of Pharmacology, Weill Cornell Medical College, New York, NY 10065, USA and Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID http://orcid.org/0000-0001-7065-4534
Ricardo A Pires3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal. rpires@i3bs.uminho.pt pashkuleva@i3bs.uminho.pt and ICVS/3Bs - PT Government Associate Laboratory, Braga/Guimarães, Portugal.ORCID http://orcid.org/0000-0002-9197-0138
Iva Pashkuleva3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal. rpires@i3bs.uminho.pt pashkuleva@i3bs.uminho.pt and ICVS/3Bs - PT Government Associate Laboratory, Braga/Guimarães, Portugal.ORCID http://orcid.org/0000-0001-6818-3374
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2M
Radioiodinated Multifunctional PARP1 Imaging Probes for Diagnosis and TherapyR01CA204441 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PILLARSETTY, NAGAVARAKISHORE · 2016 to 2020
$2.9M
Development and validation of an intraoperative imaging agent for the peripheral nervous systemR01EB029769 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI PILLARSETTY, NAGAVARAKISHORE · 2020 to 2023
Spheroids recapitulate the organization, heterogeneity and microenvironment of solid tumors. Herein, we targeted spatiotemporally the accelerated metabolism of proliferative cells located on the spheroid surface that ensure structure maintenance and/or growth. We demonstrate that phosphorylated carbohydrate amphiphile acts as a potent antimetabolite due to glycolysis inhibition and to in situ formation of supramolecular net around spheroid surface where alkaline phosphatase is overexpressed. The efficiency of the treatment is higher in spheroids as compared to the conventional 2D cultures because of the 2-fold higher expression of glucose transporter 1 (GLUT1). Moreover, treated spheroids do not undergo following relapse.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Aromatic carbohydrate amphiphile disrupts cancer spheroids and prevents relapse. · full record | OpenQuestion